OptimizeRx Corporation (OPRX) News
Filter OPRX News Items
OPRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OPRX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest OPRX News From Around the Web
Below are the latest news stories about OPTIMIZERX CORP that investors may wish to consider to help them evaluate OPRX as an investment opportunity.
OptimizeRx downgraded to "sector perform" by RBC amid slower growth outlookRBC Capital Markets has downgraded OptimizeRx Corp (NASDAQ:OPRX) to "sector perform," reflecting a tempered outlook on the company's growth prospects. RBC analysts cited challenges in the company's direct-to-consumer segment, particularly as clients transition to a self-service model that generates lower revenue but offers higher margins. This shift, coupled with weaker bookings attributed to the timing of the Medicx acquisition in late 2023, is expected to dampen revenue growth through the first half of 2025. |
Is There An Opportunity With OptimizeRx Corporation's (NASDAQ:OPRX) 49% Undervaluation?Key Insights OptimizeRx's estimated fair value is US$9.58 based on 2 Stage Free Cash Flow to Equity OptimizeRx's... |
OptimizeRx price target lowered to $13 from $17 at B. RileyB. Riley analyst Kyle Bauser lowered the firm’s price target on OptimizeRx (OPRX) to $13 from $17 and keeps a Buy rating on the shares after the company announced that CEO William Febbo will be departing to pursue other opportunities and that its President was appointed interim CEO while the company conducts a search for a permanent replacement. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analys |
Lake Street reiterates Buy on OptimizeRx after ‘surprising’ CEO departureLake Street was surprised at the news OptimizeRx’s (OPRX) CEO Will Febbo will be resigning December 31st. While the firm believes President Steve Silvestro is “a capable backfill,” it notes the timing seems odd. Typically, planned transitions are revealed around the normal earnings cycle, rather than two days before Christmas. Lake Street does not think Feebo’s departure was due to concerns around out-year expectations. With that said, the firm says it is also not blind to the stock’s underperfo |
OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEOWALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that William J. Febbo, Chief Executive Officer (CEO) and Board Member, will be departing the Company, effective as of December 31, 2024, to pursue other opportunities. Mr. Febbo will provide the Company with advisory services through Ma |
US Penny Stocks To Watch In November 2024As the U.S. stock market experiences a resurgence, with major indexes on track for weekly gains and Bitcoin reaching new all-time highs, investors are exploring diverse opportunities to capitalize on these trends. Penny stocks, often representing smaller or newer companies, remain an intriguing option despite their historical connotations. They can offer a unique blend of value and growth potential when supported by strong financial fundamentals, presenting investors with promising avenues... |
OptimizeRx to Participate in Upcoming Investor ConferencesWALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: 13th Annual ROTH Technology Conference, New York City, November 19th – 20th, 2024Canaccord Genuity’s 2024 CG MedTech, Diagnostics and Digital Health & Servi |
OptimizeRx Corp (OPRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts ...OptimizeRx Corp (OPRX) reports strong revenue growth and AI advancements, but faces hurdles in DTC transition and net loss impacts. |
OptimizeRx Corp. (OPRX) Surpasses Q3 Earnings EstimatesOptimizeRx (OPRX) delivered earnings and revenue surprises of 100% and 14.55%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
OptimizeRx Reports Third Quarter 2024 Financial Results- Q3 revenue of $21.3 million, increasing 30% year-over-year - Q3 gross profit increased 37% year-over-year to $13.4 million with a gross margin of 63% - Won 5 DAAP deals during Q3 WALTHAM, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended September 30, 2024. Quarter |